H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 report. The firm says Ohtuvayre beat its forecasts. Initial receptivity among key prescribing physicians appears highly favorable and indicative of broad market acceptance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma Faces Financial Risks Amid Medicaid Rebate Program Compliance Challenges
- Verona Pharma Reports Strong Q3 Launch for COPD Drug
- Verona Pharma reports Q3 EPS (7c), consensus (50c)
- Verona Pharma price target raised to $64 from $50 at Wells Fargo
- Verona Pharma price target raised to $45 from $38 at Jefferies